The study aimed to develop and validate a predictive nomogram for assessing the risk of endoscopic hemostasis failure in cirrhotic patients presenting with acute esophagogastric variceal bleeding (EGVB). EGVB is a severe complication of portal hypertension, with a high mortality rate, especially if endoscopic hemostasis fails.
The study aimed to develop and validate a predictive nomogram for assessing the risk of endoscopic hemostasis failure in cirrhotic patients presenting with acute esophagogastric variceal bleeding (EGVB). EGVB is a severe complication of portal hypertension, with a high mortality rate, especially if endoscopic hemostasis fails. Conducted as a retrospective single-center study, 296 patients treated between January 2020 and February 2025 were analyzed. Patients were divided into successful (n=273) and failed (n=23) endoscopic hemostasis groups, with failure defined as rebleeding within five days or inability to control hemorrhage per Baveno VII criteria.
Four independent predictors of failure were identified: Shock Index (SI > 1.2), Red Color (RC) sign, active bleeding during endoscopy, and Child-Turcotte-Pugh (CTP) score. Using LASSO regression and multivariate logistic regression, a nomogram was developed with the formula: Logit (P) = −3.548 + 1.695×SI + 2.303×RC sign + 1.785×Active bleeding + 0.46×CTP score. The nomogram demonstrated excellent predictive performance with an AUC of 0.890, outperforming traditional scoring systems like CTP, MELD, and Rockall.
Risk stratification classified patients into low, medium, and high-risk categories, with failure rates of 0%, 5.7%, and 19.2%, respectively. High-risk patients require ICU-level monitoring and immediate interventions such as secondary endoscopy, balloon tamponade, or TIPS in case of rebleeding. The study highlights the importance of hemodynamic stability (SI), endoscopic findings (RC sign and active bleeding), and liver function (CTP score) in predicting failure. While the nomogram showed promising results, the study’s single-center retrospective design limits external validation. Future research should incorporate imaging modalities and AI-driven analysis for enhanced precision.
Introduction: Endoscopic metabolic therapies have emerged as less invasive alternatives to bariatric surgery for patients with obesity and poorly controlled type 2 diabetes mellitus (T2DM). The EndoBarrier duodenal-jejunal bypass liner (DJBL) is an endoscopically placed...
Introduction: Endoscopic ultrasound (EUS)-guided transmural drainage is the standard minimally invasive treatment for symptomatic necrotizing pancreatitis. However, the optimal timing of direct endoscopic necrosectomy (DEN) following drainage remains uncertain. While the conventional step-up approach reserves...
Introduction: Bevacizumab is widely used in metastatic colorectal cancer (mCRC) because of its survival benefits but is associated with impaired wound healing, gastrointestinal perforation, and bleeding. These concerns often lead clinicians to delay endoscopic procedures...
Introduction: Endoscopic submucosal dissection (ESD) enables en bloc resection of large colorectal neoplasms with excellent oncological outcomes. However, concerns about perforation have limited its widespread adoption. This large prospective multicenter study evaluated the incidence, risk...
Introduction: Obesity has become one of the greatest global health challenges. New incretin-based therapies—including semaglutide, tirzepatide, resmetirom, and SGLT2 inhibitors such as empagliflozin—have transformed the treatment of obesity, diabetes, and MASLD. However, many patients discontinue...
Introduction: Endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) is the standard technique for diagnosing solid pancreatic lesions. Traditionally, biopsy specimens are processed for cytology, often requiring on-site cytopathology support. This multicenter prospective study evaluated whether directly placing...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.